CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) [Abstract] Total current assets Total assets Total current liabilities Total liabilities Total stockholders’ deficit Beginning balance Ending balance Total liabilities, redeemable convertible preferred stock and stockholders’ deficit CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) [Abstract] Total operating expenses Total operating loss Total other income (expense) Net loss Net loss Net loss applicable to common stockholders CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) [Abstract] Net cash from operating activities Net cash used in operating activities Net cash flows from financing activities NET DECREASE IN CASH AND CASH EQUIVALENTS Amount expanded in cash CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT (UNAUDITED) [Abstract] Beginning balance Ending balance Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at March 31, 2026 and December 31, 2025, redemption value: $7,966,000, liquidation value: $1,760,000 at March 31, 2026 Beginning balance (in Shares) Ending balance (in Shares) Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in Shares) Beginning balance (in Shares) Ending balance (in Shares) Class of Stock [Axis] Equity Components [Axis] Basis of Presentation and Liquidity [Abstract] Accrued Expenses and Other [Abstract] Total Accrued expenses Convertible Notes Payable – Related Party [Abstract] Long-Term Debt, Type [Axis] Fair Value of Financial Instruments [Abstract] Derivative Instrument [Axis] Derivative Liability - Contingent Interest Balance Balance Derivative liabilities (Note 6) Fair value of derivative liability Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Axis] Measurement Input Type [Axis] Stock-Based Compensation [Abstract] Statement of Income Location, Balance [Axis] Outstanding at beginning of period (in Shares) Outstanding at end of period (in Shares) Outstanding at beginning of period (in Dollars per share) Outstanding at end of period (in Dollars per share) Common Stock Warrants [Abstract] Outstanding at beginning of period (in Shares) Outstanding at end of period (in Shares) Outstanding at beginning of period (in Dollars per share) Outstanding at end of period (in Dollars per share) Financial Instrument [Axis] Loss Per Share [Abstract] Antidilutive Securities [Axis] Common Stock [Abstract] Convertible Line of Credit - Related Party and Supplemental Convertible Lines of Credit - Related Party [Abstract] Segments [Abstract] Segments [Axis] Commitments and Contingencies [Abstract] Leases [Abstract] Galectin Sciences LLC [Abstract] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Amendment Flag Document Fiscal Period Focus Current Fiscal Year End Date Current assets: Cash and cash equivalents Prepaid expenses and other current assets Other LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable Accrued dividends payable Convertible notes payable and accrued interest, net of debt discounts – related party (Note 5) Borrowing and accrued interest under convertible line of credit, net of debt discount – related party (Note 10) Commitments and contingencies (Note 12) Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in Shares) Series C 6% super dividend redeemable convertible preferred stock, shares issued (in Shares) Series C 6% super dividend redeemable convertible preferred stock, redemption value Series C 6% super dividend redeemable convertible preferred stock liquidation value Stockholders’ equity (deficit): Undesignated stock, $0.01 par value; 20,000,000 shares authorized at March 31, 2026 and December 31, 2025 20,000,000 shares designated at March 31, 2026 and December 31, 2025, respectively Undesignated stock, par value (in Dollars per share) Undesignated stock, shares authorized (in Shares) Undesignated stock, shares designated (in Shares) Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,185,000 and 1,210,000 issued and outstanding at March 31, 2026 and December 31, 2025, respectively, liquidation value $1,210,000 at March 31, 2026 Series A 12% convertible preferred stock, shares authorized (in Shares) Series A 12% convertible preferred stock, shares issued (in Shares) Series A 12% convertible preferred stock, shares outstanding (in Shares) Series A 12% convertible preferred stock, liquidation value Common stock, $0.001 par value; 150,000,000 shares authorized at March 31, 2026 and December 31, 2025, 65,856,898 and 65,201,995 issued and outstanding at March 31, 2026 and December 31, 2025, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized (in Shares) Common stock, issued (in Shares) Issuance of common stock (in Shares) Common stock, outstanding (in Shares) Additional paid-in capital Accumulated deficit Operating expenses: Research and development General and administrative Other income (expense): Interest income Change in fair value of derivatives Change in fair value of derivative Net loss per common share — basic (in Dollars per share) Net loss per common share — diluted (in Dollars per share) Weighted average common shares outstanding — basic (in Shares) Weighted average common shares outstanding — diluted (in Shares) CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash flows from operating activities: Stock-based compensation expense Amortization of right to use lease asset Non-cash interest expense Change in fair value of derivative liabilities Fair Value Adjustment Changes in operating assets and liabilities: Accounts payable, accrued expenses and other liabilities Accrued interest on convertible debt - related party CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from exercise of stock options Proceeds from lines of credit (in Dollars) NONCASH FINANCING ACTIVITIES: Payment of preferred stock dividends in common stock Noncash right to use lease asset Series A 12% convertible preferred stock dividend Series A 12% convertible preferred stock dividend (in Shares) Series C super dividend redeemable convertible preferred stock dividend Series C super dividend redeemable convertible preferred stock dividend (in Shares) Stock-based compensation expense, net of shares forfeited to cover tax withholding Stock-based compensation expense, net of shares forfeited to cover tax withholding (in Shares) Conversion of Series A preferred to common stock Conversion of Series A preferred to common stock (in Shares) Common stock, shares issued (in Shares) Issuance of common stock from exercise of stock options Issuance of common stock from exercise of stock options (in Shares) Exercised (in Shares) Interest expense Interest expense Preferred stock dividends Preferred stock dividends Prepaid expenses and other assets Series A 12% Convertible Preferred Stock [Member] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Deficit [Member] Basis of Presentation and Liquidity Accrued Expenses and Other Accrued Expenses Legal and accounting fees Accrued compensation Lease liability Current lease liability Accrued research and development costs and other Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Convertible Notes Payable - Related Party Fair Value of Financial Instruments Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis Key Assumptions Used in Model at Inception Derivative liability, measurement input Term Roll Forward of Derivative Liability - Contingent Interest Stock-Based Compensation Components of Stock-Based Compensation Expense Total stock-based compensation expense Amortized expense (in Dollars) Stock Option Activity Granted (in Shares) Granted (in Dollars per share) Exercised (in Dollars per share) Options forfeited/cancelled (in Dollars per share) Weighted Average Assumptions Used to Determine Fair Value of Options Granted Risk-free interest rate Risk free interest rate